LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
- Conditions
- Liver CancerProstatic CancerBrain CancerKidney CancerHead and Neck CancerSpinal NeoplasmArrhythmias, CardiacBreast CancerPancreatic Cancer
- Registration Number
- NCT05184790
- Lead Sponsor
- University of Sydney
- Brief Summary
This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.
Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.
- Detailed Description
This observational study will access routinely acquired radiation therapy treatment data from 300 patients including brain, breast, head and neck, kidney, liver, pancreas, prostate, spine and cardiac anatomic sites. At least 30 patients will be recruited from each anatomic site to enable sufficient data for the markerless tracking method training, testing and validation. The clinical data will be used to develop, train, test and validate a markerless target tracking method.
After the treatment, the ground truth and the variability in the ground truth will be computed. The patient images, the markerless tracking results, the ground truth and the variability will be uploaded to an in-house developed clinical trial learning system. Uploading additional data to the learning system automatically triggers the model building of the deep learning system. In this manner, the learning system gets both more accurate and more robust with each patient accrued. As the patient data accrues, the primary hypothesis of targeting accuracy can be tested.
The developed markerless tracking software will be applied by study personnel to the treatment imaging data for each anatomic site using five-fold cross-validation where 80% of the data is used for training and the remaining unseen 20% of the data is used for testing. Target positions produced by the markerless tracking will be compared with a 'ground truth'.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
- Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.
- Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.
- Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.
- Provides written informed consent.
- Less than 18 years of age
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Accuracy of markerless tracking 3 years Proportion of markerless tracking within 5 mm of the ground truth for each of nine anatomical sites (cohorts)
- Secondary Outcome Measures
Name Time Method Clinical acceptability of markerless tracking system 3 years Proportion of radiation therapists considering the markerless tracking system acceptable using a survey
Trial Locations
- Locations (4)
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Royal North Shore Hospital
🇦🇺Saint Leonards, New South Wales, Australia
Alfred Health
🇦🇺Melbourne, Victoria, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia